文献速递白血病

急性髓系白血病通过流式细胞术可测量残留病监测提前检测复发及其演变

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.
PubMed 文献 · Leukemia · 2024-06-18

该研究评估流式细胞术可测量残留病(Flow-MRD)监测对高危急性髓系白血病/骨髓增生异常患者即将发生复发的诊断性能,纳入136例真阳性(复发前中位2.45个月的骨髓)和155例真阴性(持续缓解期骨髓);最佳阈值为0.040%时敏感性和特异性分别为74%和87%,≥0.1%时为51%和98%;计算性Flow-MRD(C-Flow-MRD)识别的最佳阈值为0.036%和0.082%,敏感性相当;HLADRlow或CD34+CD38low(LSC型)亚群的异常贡献最大临床准确性(56%敏感性、90%特异性),并在>40%的86对配对MRD与复发样本中在原始细胞内快速扩增。

要点

  • 最佳Flow-MRD阈值为0.040%,复发临床敏感性74%、特异性87%。
  • Flow-MRD≥0.1%时敏感性51%、特异性98%。
  • FLT3突变AML复发动力学显著更高(0.92 log10/月 vs 0.78 log10/月)。

核心结论

  • 流式MRD监测可检测高危AML的MRD复发,计算分析可能增强其评估。

研究设计与样本

  • 研究纳入136例真阳性(复发前中位2.45个月的骨髓)和155例真阴性(持续缓解期骨髓)的队列,评估Flow-MRD对即将复发诊断性能。

主要发现

  • 最佳Flow-MRD阈值为0.040%时,复发临床敏感性和特异性分别为74%和87%(Flow-MRD≥0.1%时为51%和98%)。
  • 中位复发动力学为0.78 log10/月,FLT3突变AML显著更高为0.92 log10/月。
  • C-Flow-MRD生成最佳MRD阈值0.036%和0.082%,临床敏感性与标准分析相当。
  • C-Flow-MRD识别的HLADRlow或CD34+CD38low(LSC型)亚群异常贡献最大临床准确性(56%敏感性、90%特异性)。
  • 在86对配对MRD与复发样本中,>40%的样本显示这些异常在原始细胞内快速扩增。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) surveillance in acute myeloid leukemia (AML) may identify patients destined for relapse and thus provide the option of pre-emptive therapy to improve their outcome. Whilst flow cytometric MRD (Flow-MRD) can be applied to high-risk AML/ myelodysplasia patients, its diagnostic performance for detecting impending relapse is unknown. We evaluated this in a cohort comprising 136 true positives (bone marrows preceding relapse by a median of 2.45 months) and 155 true negatives (bone marrows during sustained remission). At an optimal Flow-MRD threshold of 0.040%, clinical sensitivity and specificity for relapse was 74% and 87% respectively (51% and 98% for Flow-MRD ≥ 0.1%) by 'different-from-normal' analysis. Median relapse kinetics were 0.78 log10/month but significantly higher at 0.92 log10/month for FLT3-mutated AML. Computational (unsupervised) Flow-MRD (C-Flow-MRD) generated optimal MRD thresholds of 0.036% and 0.082% with equivalent clinical sensitivity to standard analysis. C-Flow-MRD-identified aberrancies in HLADRlow or CD34+CD38low (LSC-type) subpopulations contributed the greatest clinical accuracy (56% sensitivity, 90% specificity) and notably, by longitudinal profiling expanded rapidly within blasts in > 40% of 86 paired MRD and relapse samples. In conclusion, flow MRD surveillance can detect MRD relapse in high risk AML and its evaluation may be enhanced by computational analysis.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. McCarthy N, Gui G, Dumezy F, et al. Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance. Leukemia. 2024. PMID: 38890448. doi:10.1038/s41375-024-02300-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。